Biotech / Medical
bluebird bio Inc.
An SI Board Since November 2013
Posts SubjectMarks Bans Symbol
162 42 0 BLUE
Emcee:  Biotech Jim Type:  Moderated
I have made a few bluebird houses and they had bluebirds occupy them, but that is not the reason this board is starting up. bluebird bio Inc. is a nascent biotech company that has the potential to be a disruptive force in this space.
Here is the overview of BLUE from their website:

Gene Therapy - True Personalized Medicine

"Our objective is to develop and commercialize a next generation of products based on the transformative potential of gene therapy as a one-time treatment option for patients with severe genetic and orphan diseases. Central to this effort is a collective determination within our company to provide these patients with hope for a better life in the face of limited or no long-term safe and effective treatment options."

"Our approach represents a highly personalized, important new therapeutic modality for patients with severe genetic and orphan diseases with significant unmet medical need. We have clinical-stage programs in development for childhood cerebral adrenoleukodystrophy, beta-thalassemia and sickle cell disease, as well as a preclinical oncology program in the chimeric antigen receptor (CAR) T cells field under a collaboration with Celgene Corporation."

"Our gene therapy process involves inserting genetic material into the patient's own cells ex vivo, then re-introducing the cells to the patient. For beta-thalassemia, sickle cell disease and adrenoleukodystrophy, we insert a functional copy of the malfunctioning gene into the patient's hematopoietic stem cells (HSCs), with the goal of genetically modifying a patient's own cells to fundamentally correct or address the genetic basis underlying a disease. In oncology, the gene therapy process targets a different cell type, called T cells. In this case, genetic sequences are inserted into a patient's own T cells and are intended to program the T cells to specifically recognize and attack cancer cells. In all cases, gene therapy has the potential to change the way patients are treated by correcting the underlying genetic defect that is the cause of their disease or by providing additional functionality that can eliminate the disease, rather than offering solutions that only address their symptoms. Accordingly, we believe gene therapy has the potential to provide transformative disease modifying effects with life-long clinical benefits based on a single therapeutic administration."

BLUE had its IPO priced at $17/share, and was a darling on Wall Street as it opened on its IPO day, at $25.50 and closed that day at $26.91. The stock has recently dropped back to the IPO price area.

I was drawn to BLUE based on its CAR T technology, developed by Carl June, MD, a specialist in T cell biology and lymphocyte activation at the Perelman School of Medicine at the University of Pennsylvania. This is an immunotherapy approach, and here is a lecture on engineering T cells to cure cancer.

Here is a presentation by the CEO Nick Leschly at TEDxBoston on gene therapy.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
162Every time juno gets a kick, blue rides along. But this is (likely) juno's scaram(o)uche-January 22
161Bad judgement, just bad. Let the principal investigator discuss the work. Dramscaram(o)uche-11/1/2017
160BLUE up 22% after hours on positive trial data for CAR-T candidate bb2121 BluebiJulius Wong-11/30/2016
159The U.S. Food and Drug Administration is allowing Bluebird to treat beta thalassscaram(o)uche-9/8/2016
158Small biotech Global Blood Therapeutics ( GBT) soared in heavy trading on the stThe Ox-6/10/2016
157 [graphic] [graphic]The Ox-6/9/2016
156Bluebird bio's gene therapy candidate for rare X chromosome-linked disorder Julius Wong14/20/2016
155>> and cmrx << Been looking for that post. Nice timing. ;-( Tscaram(o)uche-1/11/2016
154Back in at 44 with a token position. Token = 2% of my former position, speakingscaram(o)uche-1/11/2016
153Anyway, it was a good thought and it appears that market-in-general looked for ascaram(o)uche-12/16/2015
152chuckle -- i hesitated...would have been a nice scalp indeed. still keeping an mopgcw-12/16/2015
151That was 20% upside in a few days, hope you pulled trigger and sorry I wasn'scaram(o)uche-12/16/2015
150Now for an on topic post... I must apologize to readers of this board for my laBiotech Jim112/9/2015
149I like that FierceBiotech is calling the IV formulation the "liquid versionBiotech Jim-12/9/2015
148O.T. re. cara...... siliconinvestor.comscaram(o)uche-12/9/2015
147Biotech Jim and just plain Jim. ;-)scaram(o)uche-12/9/2015
146Cara up huge premkt. Nice!Robohogs-12/9/2015
145Hey, George. Price to book has (un)grown to appealing, but, no, I'm not. Rscaram(o)uche-12/8/2015
144getting crushed. started poking around. you buying here?mopgcw-12/7/2015
143 ASH thoughts, Dan Marks..... biotechr.comscaram(o)uche-12/4/2015
142 8:24 am Bluebirdbio sells off after updating data abstracts at ASH; two B0/B0 gJulius Wong-11/5/2015
141 Biotech Stock Mailbag: New Sarepta Risk, Zafgen Patient Death, Bluebird Gene ThJulius Wong-10/19/2015
140>> Following approximately seven years of transfusion independence, subjecscaram(o)uche-10/19/2015
139To many, this has been biotech's darling..... over-valued. Today marked scaram(o)uche-9/25/2015
138(Oxford, UK, 16th July 2015) Immunocore Limited, a world-leading biotechnology cnigel bates-7/26/2015
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.